In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Eton Pharmaceuticals (ETON), with a price target of $18.00. The company’s shares closed last Friday at $8.28, close to its 52-week high of $9.12.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 13.3% and a 39.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Biospecifics Technologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eton Pharmaceuticals with a $15.00 average price target.
See today’s analyst top recommended stocks >>
Based on Eton Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $20K and GAAP net loss of $4.73 million. In comparison, last year the company had a GAAP net loss of $3.25 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. Its portfolio consists of injectable, oral liquid, ophthalmic products pipelines. The company was founded in April 2017 and is headquartered in Deer Park, IL.
